Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:clinicalTrialPhase |
Phase 1
NCT04093596 |
| gptkbp:developedBy |
gptkb:Allogene_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALLO-715
|
| gptkbp:intendedUse |
multiple myeloma
|
| gptkbp:mechanismOfAction |
gene therapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:source |
donor-derived T cells
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:targetAudience |
relapsed/refractory multiple myeloma patients
|
| gptkbp:treatment |
allogeneic CAR-T
|
| gptkbp:bfsParent |
gptkb:Allogene_Therapeutics
|
| gptkbp:bfsLayer |
7
|